Jin Yunbo, Lin Xiaoxi, Li Wei, Hu Xiaojie, Ma Gang, Wang Wei
Department of Plastic Surgery, Shanghai 9th People's Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, People's Republic of China.
J Vasc Surg. 2008 Jun;47(6):1292-9. doi: 10.1016/j.jvs.2008.01.010. Epub 2008 Apr 3.
Treatment of congenital venous malformations poses a major clinical challenge. Great successes have been achieved with ethanol sclerotherapy in most lesions; however, severe complications are more likely to occur when more ethanol is used.
This study evaluated the safety and efficacy of a new sclerotherapy treatment that uses absolute alcohol and bleomycin A5. We evaluated our experience to present a safe treatment method for venous malformations.
The study population comprised 201 patients. Before treatment, lesions were categorized according to magnetic resonance imaging features: 120 patients had limited venous malformations, and 81 had infiltrating venous malformations. Percutaneous sclerotherapy was performed by direct injection of absolute alcohol and bleomycin A5 under fluoroscopy. The mean dose of the two medicines was 3.4 mL and 3.7 mg, respectively. We investigated 592 sclerotherapy sessions. A retrospective study was performed of medical records and color photographs and magnetic resonance imaging before and after treatment The mean follow-up was 29 months (range, 12-65 months).
After embolization of the drainage vein with ethanol, a subsequent sclerosis therapy with bleomycin A5 was judged beneficial in 196 of 201 patients. Among the 196 responders, 56 showed disappearance of their chief symptoms, 42 showed improvement to nearly normal, and 62 showed marked improvement. The best response to our treatment was among the patients with limited venous malformations, with 114 (95%) showing at least marked improvement. Complications were tissue necrosis in 6 sessions, peripheral nerve palsy in 5, pigmentation in 10, blistering in 5, and 87 sessions resulted in transient side effects related to bleomycin A5, such as fever and gastrointestinal irritation. All were self-limited. No major complications such as cardiopulmonary collapse or pulmonary fibrosis were observed.
Percutaneous sclerotherapy of venous malformations using absolute ethanol and bleomycin A5 is safe and effective. The simplicity, speed, and safety of sclerotherapy, combined with the quality and stability of the outcome achieved with our novel procedure, may make the technique the choice for treatment of venous malformations.
先天性静脉畸形的治疗是一项重大的临床挑战。乙醇硬化疗法在大多数病变中已取得巨大成功;然而,使用更多乙醇时更易发生严重并发症。
本研究评估了一种使用无水乙醇和博来霉素A5的新型硬化疗法的安全性和有效性。我们评估了自身经验,以提出一种治疗静脉畸形的安全方法。
研究人群包括201例患者。治疗前,根据磁共振成像特征对病变进行分类:120例患者为局限性静脉畸形,81例为浸润性静脉畸形。在透视引导下通过直接注射无水乙醇和博来霉素A5进行经皮硬化疗法。两种药物的平均剂量分别为3.4 mL和3.7 mg。我们对592次硬化疗法进行了调查。对治疗前后的病历、彩色照片和磁共振成像进行了回顾性研究。平均随访时间为29个月(范围12 - 65个月)。
在用乙醇栓塞引流静脉后,随后用博来霉素A5进行硬化治疗,在201例患者中有196例被判定有益。在这196例有反应的患者中,56例主要症状消失,42例改善至接近正常,62例显著改善。对我们治疗反应最佳的是局限性静脉畸形患者,其中114例(95%)至少有显著改善。并发症包括6次出现组织坏死,5次出现周围神经麻痹,10次出现色素沉着,5次出现水疱,87次出现与博来霉素A5相关的短暂副作用,如发热和胃肠道刺激。所有这些均为自限性。未观察到心肺衰竭或肺纤维化等严重并发症。
使用无水乙醇和博来霉素A5进行静脉畸形的经皮硬化疗法安全有效。硬化疗法的简便性、快速性和安全性,以及我们新方法所取得的治疗效果的质量和稳定性,可能使该技术成为治疗静脉畸形的选择。